ZIVO Bioscience Statistics
Total Valuation
ZIVO Bioscience has a market cap or net worth of 38.78 million. The enterprise value is 39.54 million.
| Market Cap | 38.78M |
| Enterprise Value | 39.54M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ZIVO Bioscience has 3.88 million shares outstanding. The number of shares has increased by 35.02% in one year.
| Current Share Class | 3.88M |
| Shares Outstanding | 3.88M |
| Shares Change (YoY) | +35.02% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 37.77% |
| Owned by Institutions (%) | 0.12% |
| Float | 1.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 185.51 |
| PB Ratio | -11.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.66 |
| EV / Sales | 189.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.08
| Current Ratio | 0.08 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -305.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1,001.91% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 276.82% |
| Revenue Per Employee | 29,861 |
| Profits Per Employee | -1.21M |
| Employee Count | 7 |
| Asset Turnover | 0.40 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.43% in the last 52 weeks. The beta is 0.18, so ZIVO Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -52.43% |
| 50-Day Moving Average | 13.18 |
| 200-Day Moving Average | 16.70 |
| Relative Strength Index (RSI) | 44.26 |
| Average Volume (20 Days) | 1,334 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 42.69 |
Income Statement
In the last 12 months, ZIVO Bioscience had revenue of 209,025 and -8.49 million in losses. Loss per share was -2.27.
| Revenue | 209,025 |
| Gross Profit | 66,209 |
| Operating Income | -8.46M |
| Pretax Income | -8.49M |
| Net Income | -8.49M |
| EBITDA | n/a |
| EBIT | -8.46M |
| Loss Per Share | -2.27 |
Balance Sheet
The company has 57,222 in cash and 819,695 in debt, giving a net cash position of -762,473 or -0.20 per share.
| Cash & Cash Equivalents | 57,222 |
| Total Debt | 819,695 |
| Net Cash | -762,473 |
| Net Cash Per Share | -0.20 |
| Equity (Book Value) | -3.29M |
| Book Value Per Share | -0.86 |
| Working Capital | -3.33M |
Cash Flow
| Operating Cash Flow | -3.08M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 31.68% |
| Operating Margin | -4,045.65% |
| Pretax Margin | -4,059.73% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZIVO Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.02% |
| Shareholder Yield | -35.02% |
| Earnings Yield | -21.88% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 27, 2023. It was a reverse split with a ratio of 0.1666667.
| Last Split Date | Oct 27, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1666667 |
Scores
ZIVO Bioscience has an Altman Z-Score of -406.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -406.49 |
| Piotroski F-Score | 2 |